Pharsight

Oracea generic

Oracea is an anti-inflammatory drug owned by Galderma Labs Lp. It contains the active ingredient doxycycline, and was first authorized for market use on May 26, 2006. The drug, available in capsule;oral dosage forms, is used primarily for the treatment of only inflammatory lesions (papules and pustules) of rosacea. Oracea holds a total of 11 patents, 5 of which have already expired.

When will Oracea generic be available?

The generic version of Oracea is due to be released after December 19, 2027. This release date is set by the expiration of the last patent for Oracea, US7749532, named 'Once daily formulations of tetracyclines', which expires on the same date.

Oracea uses

Oracea is used as a treatment for inflammatory lesions (papules and pustules) of rosacea. Its effectiveness in treating these conditions is due to its active ingredient doxycycline, which acts as an anti-inflammatory agent.

Oracea patent expiration

Oracea holds 11 patents, with the remaining unexpired 6 centered around 'Once daily formulations of tetracyclines'. The last of these patents, US7749532, is expected to expire on December 19, 2027, paving the way for Oracea generics to hit the market. Below are the details of the patent:

Litigations filed on Oracea

Oracea dosage

Want to ask something?